Atlas Trials

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Clinical trial NCT05480501 · UNKNOWN

Trial details

NCT number
NCT05480501
Sponsor
Beijing Immunochina Medical Science & Technology Co., Ltd.
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
Leukemia
Start date
2022-07-11
Primary completion
2024-08-01
Enrollment
9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.